These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 10598586)

  • 21. Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR).
    Loinder K; Söderström M
    J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):191-6. PubMed ID: 15336696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription.
    Bollig A; Miksicek RJ
    Mol Endocrinol; 2000 May; 14(5):634-49. PubMed ID: 10809228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.
    Krogsdam AM; Nielsen CA; Neve S; Holst D; Helledie T; Thomsen B; Bendixen C; Mandrup S; Kristiansen K
    Biochem J; 2002 Apr; 363(Pt 1):157-65. PubMed ID: 11903058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The nuclear corepressors recognize distinct nuclear receptor complexes.
    Cohen RN; Putney A; Wondisford FE; Hollenberg AN
    Mol Endocrinol; 2000 Jun; 14(6):900-14. PubMed ID: 10847591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
    Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
    Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
    Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
    Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone.
    Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M
    Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
    Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
    Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
    Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
    J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action.
    McInerney EM; Ince BA; Shapiro DJ; Katzenellenbogen BS
    Mol Endocrinol; 1996 Dec; 10(12):1519-26. PubMed ID: 8961262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA.
    Delage-Mourroux R; Martini PG; Choi I; Kraichely DM; Hoeksema J; Katzenellenbogen BS
    J Biol Chem; 2000 Nov; 275(46):35848-56. PubMed ID: 10960470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two separate NCoR (nuclear receptor corepressor) interaction domains mediate corepressor action on thyroid hormone response elements.
    Cohen RN; Wondisford FE; Hollenberg AN
    Mol Endocrinol; 1998 Oct; 12(10):1567-81. PubMed ID: 9773980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
    Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
    J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.
    Philips A; Teyssier C; Galtier F; Rivier-Covas C; Rey JM; Rochefort H; Chalbos D
    Mol Endocrinol; 1998 Jul; 12(7):973-85. PubMed ID: 9658402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect.
    Teyssier C; Belguise K; Galtier F; Cavailles V; Chalbos D
    Mol Endocrinol; 2003 Feb; 17(2):287-99. PubMed ID: 12554755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
    Mishra SK; Mazumdar A; Vadlamudi RK; Li F; Wang RA; Yu W; Jordan VC; Santen RJ; Kumar R
    J Biol Chem; 2003 May; 278(21):19209-19. PubMed ID: 12639951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allosteric modulation of estrogen receptor conformation by different estrogen response elements.
    Wood JR; Likhite VS; Loven MA; Nardulli AM
    Mol Endocrinol; 2001 Jul; 15(7):1114-26. PubMed ID: 11435612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
    Shibata H; Spencer TE; Oñate SA; Jenster G; Tsai SY; Tsai MJ; O'Malley BW
    Recent Prog Horm Res; 1997; 52():141-64; discussion 164-5. PubMed ID: 9238851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.